SuperworthCentene CNC
- Market cap
- $34.7B
- PE
- n/m
- a loss over the last year
- Forward PE
- 15.0×
- 10y median 14.4×
- Price to sales
- 0.2×
- EV/EBIT
- 21.8×
- Revenue, 12 months
- $202.9B
- +14% on a year ago
- Net margin
- −2.5%
- Free cash flow yield
- 25.8%
Centene trades at 0.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $202.9B over the last twelve months, up 14% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $38B+6% | $39.5B+11% | $40.4B+4% | $39.8B+6% | $42B+11% | $40.8B+3% | $46.6B+15% | $48.7B+22% | $49.7B+18% | $49.7B+22% | $49.9B+7% | $53.6B+10% | |
| Cost of revenue | $856M−46% | $961M−30% | $669M−23% | $680M−23% | $692M−19% | $688M−28% | $698M+4% | $641M−6% | $651M−6% | $680M−1% | $702M+1% | $729M+14% |
| Gross profit | $37.2B+8% | $38.5B+13% | $39.7B+5% | $39.2B+7% | $41.3B+11% | $40.1B+4% | $45.9B+16% | $48.1B+23% | $49B+19% | $49B+22% | $49.2B+7% | $52.9B+10% |
| SG&A | $3B+7% | $3.5B+9% | $3.2B+7% | $2.9B−4% | $3.1B+0% | $3.2B−7% | $3.4B+4% | $3B+5% | $3.1B+3% | $3.4B+4% | $3.4B+1% | $3.1B+2% |
| $735M+54% | −$194M−31% | $1.1B−9% | $1.2B+5% | $665M−10% | $175M | $1.5B+39% | −$458M | −$7B | −$1.7B | $1.9B+21% | $1.2B | |
| Interest expense | $181M+7% | $183M+5% | $178M−1% | $176M−3% | $176M−3% | $172M−6% | $170M−5% | $170M−3% | $170M−3% | $168M−2% | $164M−4% | $153M−10% |
| Pre-tax income | $768M−24% | $24M−42% | $1.5B+6% | $1.5B+7% | $921M+20% | $347M+1346% | $1.7B+19% | −$257M | −$6.7B | −$1.5B | $2.1B+20% | $1.5B |
| $293M+9% | −$15M | $315M+21% | $370M+3% | $211M−28% | $67M | $432M+37% | $2M−100% | −$42M | −$443M | $560M+30% | $399M+19850% | |
| Net income | $469M−36% | $45M | $1.2B+3% | $1.1B+8% | $713M+52% | $283M+529% | $1.3B+13% | −$253M | −$6.6B | −$1.1B | $1.5B+18% | $1.1B |
| $0.87−32% | $0.08 | $2.16+6% | $2.16+13% | $1.36+56% | $0.56+600% | $2.63+22% | −$0.51 | −$13.50 | −$2.24 | $3.11+18% | $2.19 | |
| 541.3M−7% | 537.7M−4% | 538.1M−3% | 530.8M−4% | 523.5M−3% | 502.4M−7% | 498.2M−7% | 493.5M−7% | 491.1M−6% | 491.5M−2% | 495.6M−1% | 497.6M+1% |
Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY09 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY14 and Q4 FY18: share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x2). 3 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $47.1B | $46.3B to $48.6B | $0.10 | $0.01 to $0.14 | 12 |
| Q4 FY26 | $45.8B | $44.4B to $47.4B | −$1.10 | −$1.29 to −$0.95 | 12 |
| Q1 FY27 | $48.9B | $47.1B to $50.4B | $3.40 | $3.24 to $3.54 | 5 |
| Q2 FY27 | $49.7B | $47.9B to $51.2B | $2.28 | $2.17 to $2.37 | 5 |
| Q3 FY27 | $47.9B | $46.2B to $49.4B | $0.49 | $0.46 to $0.51 | 5 |
| Q4 FY27 | $47.7B | $45.9B to $49.1B | −$0.83 | −$0.86 to −$0.79 | 5 |
| Q1 FY28 | $50.6B | $48.8B to $52.2B | $3.70 | $3.52 to $3.85 | 6 |
| Q2 FY28 | $51.4B | $49.5B to $53B | $2.52 | $2.40 to $2.62 | 6 |
Peers
Companies in Medical - Healthcare Plans nearest Centene's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CNCCentene | $34.7B | n/m | 20.7× | 15.0× | 0.2× | +14% | −2.5% |
| HUMHumana | $50.7B | 39.9× | 20.7× | 33.7× | 0.3× | +18% | 0.9% |
| CICigna | $81.1B | 12.7× | 16.1× | 9.7× | 0.3× | +8% | 2.3% |
| ELVElevance Health | $95.4B | 19.6× | 17.6× | 16.1× | 0.5× | +6% | 2.5% |
| CVSCVS Health | $119.5B | 24.7× | 16.2× | 11.5× | 0.3× | +7% | 1.2% |
| OSCROscar Health | $9.6B | 22.3× | 47.9× | n/m | 0.6× | +43% | 3.6% |
| Peer median | $81.1B | 22.3× | 17.6× | 13.8× | 0.3× | +8% | 2.3% |
Investors who own it
Investors we follow who held Centene at the end of Jun 30, 2026, from their 13F filings.
- David EinhornGreenlight Capital2.7% of portfoliotrimmed
- Bill NygrenHarris Associates (Oakmark)1.0% of portfoliotrimmed
More on Centene
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 199Healthcare stocks with the highest free cash flow yield
- #1of 11Health insurers with the lowest price to sales ratio
- #5of 34Healthcare stocks with the lowest PEG ratio
- #5of 11Health insurers with the fastest revenue growth
- #8of 10Health insurers with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .